Shanghai Junshi Biosciences (SHJBF) Stock Price, News & Analysis

Company Overview

Shanghai Junshi Biosciences Co., Ltd. is a Shanghai-based clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative therapies in oncology, autoimmune and infectious diseases. Founded in 2012, Junshi leverages proprietary antibody technology platforms to develop novel monoclonal and bispecific antibodies. The company’s research efforts span immuno-oncology, inflammation and metabolic disorders, with an emphasis on addressing unmet medical needs in China and select international markets.

Junshi’s lead product, toripalimab, is a humanized monoclonal antibody targeting the programmed cell death protein-1 (PD-1) pathway. Toripalimab has received regulatory approval in China for multiple cancer indications, including melanoma, nasopharyngeal carcinoma and urothelial carcinoma, marking it among the first domestically developed PD-1 inhibitors on the market. The company continues to explore additional indications and combination regimens to broaden the clinical utility of toripalimab.

Beyond its flagship asset, Shanghai Junshi Biosciences maintains a diverse pipeline of antibody-based candidates. Key programs include monoclonal antibodies against CTLA-4, IL-17A and IL-6 receptors, as well as bispecific formats designed to engage multiple immune targets simultaneously. Junshi has entered strategic partnerships with global biopharmaceutical firms to advance select programs outside of China, reflecting its ambition to establish a presence in major markets such as North America and Europe.

Headquartered in Shanghai, the company operates research and manufacturing facilities in China and collaborates with academic and industry partners worldwide. Junshi’s leadership team comprises industry veterans with deep experience in biologic drug development, regulatory affairs and commercial strategy. Through its integrated capabilities and strategic alliances, Shanghai Junshi Biosciences aims to deliver next-generation therapies to patients across diverse geographies.

Key Stats

• Today's Range: C$1.97 to C$1.97
• 50-Day Range: C$1.97 to C$1.97
• 52-Week Range: C$1.24 to C$1.50
• Volume: N/A
• Average Volume: 100 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SHJBF Stock Analysis - Frequently Asked Questions

How have SHJBF shares performed this year?

Shanghai Junshi Biosciences' stock was trading at C$1.24 at the beginning of the year. Since then, SHJBF stock has increased by 58.9% and is now trading at C$1.97.

How do I buy shares of Shanghai Junshi Biosciences?

Shares of SHJBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SHJBF
• CIK: N/A
• Web: www.junshipharma.com
• Phone: 86 21 6105 8800
• Fax: N/A
• Employees: 2,568
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A